TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better.

Gabriella PietraMaria Cristina MingariLorenzo Moretta

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

IL15 and TIGIT blockade enhances the natural killer (NK) cell-mediated activity against MHC-I-deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell-mediated control.See related article by Chauvin et al., p. 5520.

Keyphrases

nk cells
high glucose
stem cells
drug induced
cell therapy
oxidative stress
deep learning
bone marrow
artificial intelligence